SRPT

Oppenheimer Upgrades Sarepta Therapeutics (SRPT)

Fintel reports that on May 14, 2024, Oppenheimer upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Perform to Outperform.

Analyst Price Forecast Suggests 29.21% Upside

As of May 8, 2024, the average one-year price target for Sarepta Therapeutics is 170.17. The forecasts range from a low of 129.28 to a high of $235.20. The average price target represents an increase of 29.21% from its latest reported closing price of 131.70.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Sarepta Therapeutics is 2,022MM, an increase of 44.09%. The projected annual non-GAAP EPS is 2.68.

What is the Fund Sentiment?

There are 882 funds or institutions reporting positions in Sarepta Therapeutics. This is an decrease of 46 owner(s) or 4.96% in the last quarter. Average portfolio weight of all funds dedicated to SRPT is 0.27%, an increase of 9.01%. Total shares owned by institutions decreased in the last three months by 1.79% to 97,175K shares. SRPT / Sarepta Therapeutics, Inc. Put/Call Ratios The put/call ratio of SRPT is 0.28, indicating a bullish outlook.

What are Other Shareholders Doing?

SRPT / Sarepta Therapeutics, Inc. Shares Held by Institutions

Janus Henderson Group holds 5,346K shares representing 5.66% ownership of the company. In its prior filing, the firm reported owning 5,782K shares , representing a decrease of 8.17%. The firm decreased its portfolio allocation in SRPT by 78.07% over the last quarter.

Capital International Investors holds 4,741K shares representing 5.02% ownership of the company. In its prior filing, the firm reported owning 1,824K shares , representing an increase of 61.54%. The firm increased its portfolio allocation in SRPT by 82.72% over the last quarter.

Avoro Capital Advisors holds 4,344K shares representing 4.60% ownership of the company. In its prior filing, the firm reported owning 4,025K shares , representing an increase of 7.35%. The firm decreased its portfolio allocation in SRPT by 23.96% over the last quarter.

Wellington Management Group Llp holds 4,128K shares representing 4.37% ownership of the company. In its prior filing, the firm reported owning 3,910K shares , representing an increase of 5.28%. The firm decreased its portfolio allocation in SRPT by 21.84% over the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,789K shares representing 2.95% ownership of the company. In its prior filing, the firm reported owning 2,777K shares , representing an increase of 0.40%. The firm decreased its portfolio allocation in SRPT by 28.63% over the last quarter.

Sarepta Therapeutics Background Information
(This description is provided by the company.)

Sarepta Therapeutics Inc. is leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with raredisease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company's programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.